Clinical Trial Update: Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy follow-up study for BIIB111 in choroideremia and BIIB112 in X-linked retinitis pigmentosa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroideremia
• X-linked Retinitis Pigmentosa

Drugs mentioned

• BIIB111
• BIIB112

Snippet

Sponsor: NightstaRx Ltd, a Biogen Company | Conditions: Choroideremia, X-Linked Retinitis Pigmentosa | Phase 3 | Status: COMPLETED